{"id":"anastrozole-plus-goserelin","safety":{"commonSideEffects":[{"rate":"null","effect":"Hot flashes"},{"rate":"null","effect":"Vaginal dryness"},{"rate":"null","effect":"Osteoporosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Anastrozole inhibits the enzyme aromatase, which is involved in the biosynthesis of estrogen. Goserelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses the production of gonadotropins, leading to a decrease in estrogen levels.","oneSentence":"Aromatase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:56:34.867Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT03701334","phase":"PHASE3","title":"A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-07","conditions":"Early Breast Cancer","enrollment":5101},{"nctId":"NCT05827081","phase":"PHASE3","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-28","conditions":"Early Breast Cancer","enrollment":1400},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":"Breast Cancer","enrollment":1939},{"nctId":"NCT05161195","phase":"PHASE4","title":"Roll-over Study to Allow Continued Access to Ribociclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-07","conditions":"Metastatic Breast Cancer","enrollment":134},{"nctId":"NCT01723774","phase":"PHASE2","title":"PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2013-04-10","conditions":"Breast Neoplasms","enrollment":84},{"nctId":"NCT03671330","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-08-29","conditions":"Breast Cancer","enrollment":327},{"nctId":"NCT03822468","phase":"PHASE2","title":"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-11","conditions":"Breast Cancer","enrollment":376},{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT02476786","phase":"PHASE2","title":"Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-17","conditions":"Breast Cancer, Cancer of Breast, Breast Neoplasms","enrollment":50},{"nctId":"NCT06953882","phase":"PHASE2","title":"Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-07-09","conditions":"HER2 Negative Breast Cancer","enrollment":140},{"nctId":"NCT03944434","phase":"PHASE2","title":"FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Sandro Pitigliani","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":116},{"nctId":"NCT06656624","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-13","conditions":"Advanced Breast Cancer","enrollment":190},{"nctId":"NCT03839823","phase":"PHASE2","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-25","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT06447623","phase":"PHASE3","title":"Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-02-01","conditions":"Advanced Breast Cancer, HR+/HER2- Breast Cancer","enrollment":184},{"nctId":"NCT02344472","phase":"PHASE3","title":"Detect V / CHEVENDO (Chemo vs. Endo)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2015-09","conditions":"Metastatic Breast Cancer","enrollment":271},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT00295646","phase":"PHASE3","title":"Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"1999-06","conditions":"Breast Cancer","enrollment":1803},{"nctId":"NCT02278120","phase":"PHASE3","title":"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-20","conditions":"Advanced Metastatic Breast Cancer","enrollment":672},{"nctId":"NCT05949541","phase":"PHASE2","title":"Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-07-26","conditions":"Breast Cancer, Advanced Breast Cancer","enrollment":265},{"nctId":"NCT05891093","phase":"PHASE3","title":"Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Breast Cancer","enrollment":766},{"nctId":"NCT05983107","phase":"PHASE2","title":"Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-07-20","conditions":"HR+/HER2- Advanced Breast Cancer, Targeted Therapy","enrollment":102},{"nctId":"NCT05801705","phase":"","title":"Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-01","conditions":"Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer, Breast Cancer Patients at Intermediate to High Risk","enrollment":700},{"nctId":"NCT05800197","phase":"","title":"Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2014-04-15","conditions":"Breast Cancer, Neoadjuvant Endocrine Therapy","enrollment":300},{"nctId":"NCT02440230","phase":"PHASE2","title":"Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2015-05","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT01989780","phase":"PHASE2","title":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2014-01","conditions":"Metastatic Breast Cancer","enrollment":160},{"nctId":"NCT05439499","phase":"PHASE3","title":"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.","status":"UNKNOWN","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2022-03-02","conditions":"Advanced Breast Cancer, Female Breast Cancer","enrollment":434},{"nctId":"NCT02603679","phase":"PHASE2","title":"Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hatschek","startDate":"2015-02","conditions":"Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor","enrollment":181},{"nctId":"NCT02592083","phase":"PHASE2","title":"Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hatschek","startDate":"2015-10","conditions":"Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor","enrollment":10},{"nctId":"NCT02532400","phase":"PHASE3","title":"Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients","status":"TERMINATED","sponsor":"Ruijin Hospital","startDate":"2016-03","conditions":"Breast Cancer","enrollment":21},{"nctId":"NCT00186121","phase":"PHASE2","title":"Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women","status":"COMPLETED","sponsor":"Stanford University","startDate":"2000-10","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT01776008","phase":"PHASE2","title":"Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-01","conditions":"Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma","enrollment":16},{"nctId":"NCT01266213","phase":"PHASE2","title":"Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2010-12","conditions":"Metastatic Breast Cancer, Estrogen Receptor Positive Tumor, Breast Cancer Nos Premenopausal","enrollment":147},{"nctId":"NCT00438321","phase":"PHASE1","title":"Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2006-09","conditions":"Metabolic Syndrome","enrollment":66},{"nctId":"NCT01368263","phase":"PHASE2","title":"Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2011-09","conditions":"Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Stage II Breast Cancer","enrollment":8},{"nctId":"NCT00053911","phase":"PHASE3","title":"Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2002-11","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT02072512","phase":"PHASE2","title":"The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Hospital Affiliated to Military Medical Science, Beijing","startDate":"2014-01","conditions":"Metastatic Breast Cancer","enrollment":180},{"nctId":"NCT00217659","phase":"PHASE2","title":"S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2005-09","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00605267","phase":"PHASE3","title":"Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-10","conditions":"Breast Cancer","enrollment":197},{"nctId":"NCT01352091","phase":"PHASE3","title":"Adjuvant AI Combined With Zoladex","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2008-05","conditions":"Breast Cancer","enrollment":670},{"nctId":"NCT00235937","phase":"PHASE2","title":"Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2001-12","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT00398489","phase":"PHASE2","title":"Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery","status":"UNKNOWN","sponsor":"Technical University of Munich","startDate":"2006-10","conditions":"Breast Cancer","enrollment":94},{"nctId":"NCT00433173","phase":"NA","title":"Insulin Sensitivity in Men With the Metabolic Syndrome","status":"SUSPENDED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2006-05","conditions":"Metabolic Syndrome","enrollment":72},{"nctId":"NCT00382057","phase":"PHASE2","title":"Testosterone Effects on Men With the Metabolic Syndrome","status":"WITHDRAWN","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-05","conditions":"Metabolic Syndrome","enrollment":72},{"nctId":"NCT00286351","phase":"PHASE4","title":"Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2005-01","conditions":"Endometriosis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fulvestrant plus Goserelin"],"phase":"phase_2","status":"active","brandName":"Anastrozole plus Goserelin","genericName":"Anastrozole plus Goserelin","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aromatase inhibitor Used for Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}